KR20210007042A - 나이브한 대상들을 위한 백신 조성물 - Google Patents

나이브한 대상들을 위한 백신 조성물 Download PDF

Info

Publication number
KR20210007042A
KR20210007042A KR1020217000812A KR20217000812A KR20210007042A KR 20210007042 A KR20210007042 A KR 20210007042A KR 1020217000812 A KR1020217000812 A KR 1020217000812A KR 20217000812 A KR20217000812 A KR 20217000812A KR 20210007042 A KR20210007042 A KR 20210007042A
Authority
KR
South Korea
Prior art keywords
acid
composition
vaccine
influenza
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217000812A
Other languages
English (en)
Korean (ko)
Inventor
한스 아르비손
안나-카린 말타이스
Original Assignee
유로씨네 백신즈 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로씨네 백신즈 에이비 filed Critical 유로씨네 백신즈 에이비
Publication of KR20210007042A publication Critical patent/KR20210007042A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020217000812A 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물 Ceased KR20210007042A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157019558A Division KR20150132092A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Publications (1)

Publication Number Publication Date
KR20210007042A true KR20210007042A (ko) 2021-01-19

Family

ID=47358019

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217000812A Ceased KR20210007042A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물
KR1020157019562A Ceased KR20150132093A (ko) 2012-12-17 2013-12-17 면역손상된 인구들에서의 사용을 위한 백신 조성물
KR1020157019558A Ceased KR20150132092A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157019562A Ceased KR20150132093A (ko) 2012-12-17 2013-12-17 면역손상된 인구들에서의 사용을 위한 백신 조성물
KR1020157019558A Ceased KR20150132092A (ko) 2012-12-17 2013-12-17 나이브한 대상들을 위한 백신 조성물

Country Status (12)

Country Link
US (2) US11065325B2 (cg-RX-API-DMAC7.html)
EP (4) EP2742952A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016502996A (cg-RX-API-DMAC7.html)
KR (3) KR20210007042A (cg-RX-API-DMAC7.html)
CN (3) CN104884085A (cg-RX-API-DMAC7.html)
AU (2) AU2013360889C1 (cg-RX-API-DMAC7.html)
BR (2) BR112015014243A8 (cg-RX-API-DMAC7.html)
CA (2) CA2895023A1 (cg-RX-API-DMAC7.html)
HK (2) HK1212611A1 (cg-RX-API-DMAC7.html)
MX (2) MX2015007753A (cg-RX-API-DMAC7.html)
RU (2) RU2661407C2 (cg-RX-API-DMAC7.html)
WO (2) WO2014095944A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243817A1 (en) * 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions
ES2927797T3 (es) * 2014-09-26 2022-11-11 Seqirus Uk Ltd Vacunación de sujetos inmunocomprometidos
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
BR112022020792A2 (pt) * 2020-04-16 2022-11-29 Bayer Ag Combinações de compostos ativos e composições fungicidas compreendendo-as
LT4135519T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A4 (en) * 2022-01-10 2026-06-17 Childrens Medical Ct Corp METHODS AND COMPOSITIONS RELATING TO THE IMMUNIZATION OF DISTINCTIVE IMMUNE PATIENTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
EP2292628A3 (en) 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
US20130243817A1 (en) 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions

Also Published As

Publication number Publication date
EP2931308A1 (en) 2015-10-21
CA2895023A1 (en) 2014-06-26
EP2931307B1 (en) 2018-09-12
BR112015014174A2 (pt) 2017-07-11
WO2014095943A1 (en) 2014-06-26
HK1212611A1 (zh) 2016-06-17
RU2015129028A (ru) 2017-01-23
RU2015129077A (ru) 2017-01-23
KR20150132093A (ko) 2015-11-25
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
US20150306204A1 (en) 2015-10-29
HK1213492A1 (zh) 2016-07-08
JP2016502997A (ja) 2016-02-01
MX2015007688A (es) 2015-09-07
CN104884085A (zh) 2015-09-02
RU2661408C2 (ru) 2018-07-16
EP2742952A1 (en) 2014-06-18
EP2931308B1 (en) 2018-10-10
US11065325B2 (en) 2021-07-20
KR20150132092A (ko) 2015-11-25
CN112826929A (zh) 2021-05-25
AU2013360889B2 (en) 2016-12-01
AU2013360890A1 (en) 2015-07-02
BR112015014243A8 (pt) 2019-10-08
AU2013360889C1 (en) 2017-06-08
CA2895028A1 (en) 2014-06-26
EP2931307A1 (en) 2015-10-21
US20150306205A1 (en) 2015-10-29
CN104870010A (zh) 2015-08-26
RU2661407C2 (ru) 2018-07-16
JP2016502996A (ja) 2016-02-01
MX2015007753A (es) 2016-01-08
WO2014095944A1 (en) 2014-06-26
BR112015014243A2 (pt) 2017-07-11
AU2013360889A1 (en) 2015-07-02
AU2013360890B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
AU2013360889B2 (en) Vaccine composition for naive subjects
JP5639760B2 (ja) インフルエンザワクチン
JP6839088B2 (ja) 手足口病ワクチン、ならびにその製造方法及び使用方法
US10233429B2 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US20090263422A1 (en) Influenza vaccine
JP2009209086A (ja) 粘膜投与型ワクチン
JP5918870B2 (ja) インフルエンザに対する改善されたワクチン接種
Maltais et al. Intranasally administered Endocine™ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets
US8535683B2 (en) Intranasal or inhalational administration of virosomes
CN113646047B (zh) 减毒活流感疫苗组合物和用于制备其的方法
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
WO2023047419A1 (en) A vaccine for coronavirus and influenza virus, and method for preparation thereof
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
Willis The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210111

Application number text: 1020157019558

Filing date: 20150717

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210119

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210316

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210316

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I